Yonsa Approval Status
- FDA approved: No
- Brand name: Yonsa
- Generic name: abiraterone acetate
- Company: Churchill Pharmaceuticals, LLC
- Treatment for: Prostate Cancer
Yonsa (abiraterone acetate) is an improved ultramicrosize formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga) in development for the combination treatment of metastatic castration-resistant prostate cancer.
Development Status and FDA Approval Process for Yonsa
| Date | Article |
|---|---|
| May 23, 2017 | Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
